Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).

被引：0
|
作者：
Sun, Hui-Chuan
Zhu, Xiao-Dong
Wang, Kui
Xue, Hui
Yang, Ning
Yang, Ying-Cheng
Chen, Yong-Jun
Ye, Feng
Kuang, Ming
Shen, Shun-Li
Huang, Cheng
机构：
[1] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Liver Surg & Transplantat, Shanghai, Peoples R China
[3] Naval Med Univ, Dept Hepat Surg 2, Eastern Hepatobiliary Surg Hosp, Affiliated Hosp 3, Shanghai, Peoples R China
[4] Naval Med Univ, Dept Hepat Surg 5, Affiliated Hosp 3, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gen Surg, Sch Med, Shanghai, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Hepatopancreatobiliary Surg, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4120
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp
    Rodrigues, Manuel
    Saint-Ghislain, Mathilde
    Ramtohul, Toulsie
    de Koning, Leanne
    Bouchez, Clementine
    Lafite, Elsa
    Ajgal, Zahra Castel
    Marret, Gregoire
    Sanchez, Raphael
    Mariani, Pascale
    Nespoulous, Sandra
    Gillon, Veronique
    Servois, Vincent
    Piperno-Neumann, Sophie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
    Grob, Jean-Jacques
    Gonzalez, Rene
    Basset-Seguin, Nicole
    Vornicova, Olga
    Schachter, Jacob
    Joshi, Abhishek
    Meyer, Nicolas
    Grange, Florent
    Piulats, Josep M.
    Bauman, Jessica R.
    Zhang, Pingye
    Gumuscu, Burak
    Swaby, Ramona F.
    Hughes, Brett G. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2916 - +
  • [33] Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
    Zhang, Wenwen
    Tong, Shuang
    Hu, Bingyang
    Wan, Tao
    Tang, Haowen
    Zhao, Feilong
    Jiao, Tianyu
    Li, Junfeng
    Zhang, Ze
    Cai, Jinping
    Ye, Huiyi
    Wang, Zhanbo
    Chen, Shiqing
    Wang, Yafei
    Li, Xuerui
    Wang, Fangzhou
    Cao, Junning
    Tian, Lantian
    Zhao, Xiaochen
    Chen, Mingyi
    Wang, Hongguang
    Cai, Shouwang
    Hu, Minggen
    Bai, Yuezong
    Lu, Shichun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
  • [34] Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma with Localized Portal Vein Tumor Thrombosis (RESOLVE): Protocol for an Open-label, Multi-center, Single-arm Trial
    Choi, Jin Woo
    Kim, Gyoung Min
    Hyun, Dongho
    Jang, Myoung-jin
    Kim, Hyo-Cheol
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2025, 48 (03) : 398 - 404
  • [35] A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma
    Lee, Choong-kun
    Hwang, Ho Kyoung
    Jeung, Hei-Cheul
    Chon, Hongjae
    Park, Hyung Soon
    Kim, Min Hwan
    Park, Mi-Suk
    Kang, Chang Moo
    Choi, Hye Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [36] Stereotactical Radiotherapy in the Hepatocellular Carcinoma (HCC). A single-center Phase II Study
    Brunner, T. B.
    Kirste, S.
    Schultheiss, M.
    Euringer, W.
    Neeff, H.
    Schulenburg, M.
    Thimme, R.
    Grosu, A. L.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 : 10 - 11
  • [37] Modified-dose capecitabine plus bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study
    Hsu, C.
    Yang, T.
    Hsu, C.
    Toh, H.
    Epstein, R. J.
    Hsiao, L.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
    O'Reilly, Eileen M.
    Perelshteyn, Anna
    Jarnagin, William R.
    Schattner, Mark
    Gerdes, Hans
    Capanu, Marinela
    Tang, Laura H.
    LaValle, Joseph
    Winston, Corinne
    DeMatteo, Ronald P.
    D'Angelica, Michael
    Kurtz, Robert C.
    Abou-Alfa, Ghassan K.
    Klimstra, David S.
    Lowery, Maeve A.
    Brennan, Murray F.
    Coit, Daniel G.
    Reidy, Diane L.
    Kingham, T. Peter
    Allen, Peter J.
    ANNALS OF SURGERY, 2014, 260 (01) : 142 - 148
  • [39] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
    Xu, Yongkang
    Fu, Shumin
    Mao, Ye
    Yi, Fengming
    Jiang, Weiming
    Feng, Long
    Wu, Jianbing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 500 - 500
  • [40] A multi-center comparative study of Atezolizumab plus Bevacivumab and Lenvatinib as primary systemic therapy for un-resectable hepatocellular carcinoma (HCC): focus on thrombotic and hemorrhagic adverse events
    Tizzani, M.
    Mazzarelli, C.
    Burlone, M.
    Carucci, P.
    Caviglia, G. P.
    Lisi, C.
    Canalis, C.
    Cesarini, L.
    Pirisi, M.
    Acquaviva, A.
    Rolle, E.
    Pochettino, P.
    Bencardino, K.
    Villa, F.
    Angiolillo, M.
    Scaldaferri, M.
    Castellana, E.
    Cattel, F.
    Airoldi, M.
    Saracco, G. M.
    Gaia, S.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S84 - S84
12345